clinical hplc and toxicology 2016/2017€¦ · clinical hplc and toxicology 2016/2017 at bio-rad,...

Clinical HPLC and Toxicology2016/2017

For ordering or additional information please contact your local Bio-Rad office or visit us at www.biorad.com | 3

Clinical HPLC

Biogenic Amines 04 − 08

Homocysteine Assay for Risk Assessment Testing 09 − 10

Bone and Mineral Testing 11 − 12

Vitamin Assays 13 − 14 33

Toxicology

Alcohol Abuse Monitoring 17 − 18

Therapeutic Drug Monitoring 19 − 26

Drug Screening 27 − 30

Overview: Analytes and Controls 31 − 33

Hard- & Software Requirements 34

OverviewClinical HPLC and Toxicology 2016/2017 At Bio-Rad, it is a priority to provide laboratorians with the appropriate resources for speciality testing, so that assays can be completed with the greatest accuracy and efficiency. Bio-Rad offers the convenienceof ready-to-use kits for the analysis of biogenic amines, homocysteine, vitamins, bone markers and alcoholabuse markers as well as for therapeutic drug monitoring and drug screening. These kits coupleconvenience with specificity, sensitivity and reliability for routine operation in the clinical laboratory.

Ordering Information • CE Marked

Catalog Description

195-5390 Urinary Catecholamines by HPLC Reagent Kit .................... 100 tests195-5391 Urinary Catecholamines by HPLC Reagent Kit, automated method ... 300 tests

Additional Required Items

195-5369 Analytical Cartridge (incl. 2 Micro-Guard™ Cartridges) ... 600 injections195-5925 Analytical Cartridge Holder..................1 unit195-5030 Micro-Guard™ Cartridge Holder ..........1 unit195-4088 Capillary Connecting Set.....................1 unit195-5976 Application CD ROM for Biogenic Amines on ASPEC™ .............1 unit195-5368 Test Mix ...............................................1 mL196-1012 Sample Vials ................................1000 vials195-5232 Piercable Caps ............................. 500 caps

4 | For ordering or additional information please contact your local Bio-Rad office or visit us at www.biorad.com

www.bio-rad.com

Clinical HPLC

Biogenic Amines

New manual method and automated method on Gilson ASPEC™

Catecholamines like dopamine, epinephrine and norepi-nephrine play important roles as neurotransmitters and hormonal signals. For example, they control the body´s response to acute and chronic stress by influencing cardiovascular and metabolic organ activities. Catecholamine-secreting tumors like pheochromocytomas and neuroblastomas dramatically influence the balance of naturally occurring catecholamines.

Bio-Rad´s Urinary Catecholamines by HPLC application is designed for the quantitative determination of free catecholamines (epinephrine, norepinephrine, dopamine) in urine for the diagnosis and follow-up of patients with pheochromocytoma and related neurogenic tumors.

In addition, this application is compatible with Bio-Rad´s Urinary Metanephrines by HPLC assay because the same analytical cartridge and mobile phase are used.

The new Urinary Catecholamines by HPLC assay features:

■■ Fast sample preparation – one disposable column instead of two

■■ Increased reliability – pH indicator in dilution reagent displays optimal pH range

■■ Excellent robustness – interfering substances eliminated during specimen preparation

■■ Maximized throughput – automated application on Gilson ASPEC™ XL or GX271 available

■■ Improved economic efficiency – increased lifetime of the analytical cartridge

Sample preparation:

■■ Type: sample purification on disposable column■■ Duration: <20 minutes

Test characteristics:

■■ Principle: Isocratic HPLC method (Reversed Phase)■■ Duration of chromatography: 11 minutes■■ Sample volume:

1 mL urine (manual method) 400 μL urine (automated method)

■■ Flow rate: 0.8 mL/min■■ Electrochemical detection: 550 mV

Urinary Catecholamines by HPLC

Biogenic Amines

Urinary Catecholamines by HPLC

Chromatogram of the Biogenic Amines Calibrator

HPLC Automation

Bio-Rad has developed automated protocols for many of our HPLC kits by making use of the Gilson ASPEC™ XL or GX-271. Each protocol is validated so you can have confidence in the results. These methods help reduce laboratory costs by dramatically decreasing labour hours. Contact your local Bio-Rad representative for more information about the Gilson ASPEC™ methods.

See Also

For items available separately, please

see “Instruction for use” or webpage.

Find separately available controls on page: 31 - 33


Catalog Description

195-5880 Plasma Catecholamines by HPLC Reagent Kit ........................................................................................... 100 tests


195-5886 Analytical Cartridge (includes 2 Micro-Guard™ cartridges) .................................................................... 500 injections195-5925 Analytical Cartridge Holder................................................................................................................................ 1 unit195-5030 Micro-Guard™ Cartridge Holder ........................................................................................................................ 1 unit195-4088 Capillary Connecting Set................................................................................................................................... 1 unit270-0336 Prefilters ......................................................................................................................................................... 10 pcs270-0338 Holder for Prefilter ............................................................................................................................................. 1 unit195-5368 Test Mix .............................................................................................................................................................1 mL


www.bio-rad.com

Clinical HPLC

Biogenic Amines

Neuroendocrine tumors are rare, but dangerous. They will cause serious cardiovascular complications and death if not recognized and properly treated.

To improve the screening for these neurochromaffin tumors the usual recommendation is that tests should combine measurements of urinary or plasma catecholamines with determinations of urinary or plasma metanephrines.

This kit is an optimized assay for the quantitative determination of catecholamines in human plasma for the diagnosis of pheochromocytoma and related neurogenic tumors.

The Plasma Catecholamines by HPLC assay features:

■■ Improved usability – simplified sample preparation■■ High confidence in results – low detection limit

Sample preparation:



■■ Principle: Isocratic HPLC method (Reversed Phase)■■ Duration of chromatography: 19 minutes■■ Sample volume: 1 mL plasma■■ Flow rate: 0.7 mL/min■■ Electrochemical detection: 550 mV

Plasma Catecholamines by HPLC

Plasma Catecholamines by HPLC

Chromatogram of the Plasma Catecholamines Calibrator

See Also

For items available separately, please see “Instruction for use” or webpage. Find separately available controls on page: 31 - 33


Catalog Description

Reagent Kit

195-5411 Urinary Metanephrines by HPLC Reagent Kit .............................................................................................. 100 tests195-5412 Urinary Metanephrines by HPLC Reagent Kit, automated method .............................................................. 200 tests


195-5369 Analytical Cartridge (includes 2 Micro-Guard™ Cartridges) ................................................................... 600 injections195-5925 Analytical Cartridge Holder................................................................................................................................ 1 unit195-5030 Micro-Guard™ Cartridge Holder ........................................................................................................................ 1 unit196-1012 Sample Vials .............................................................................................................................................. 1000 vials195-5232 Piercable caps ........................................................................................................................................... 500 caps195-5413 Test Mix .............................................................................................................................................................1 mL195-5976 Application CD ROM for Biogenic Amines on ASPEC™ ..................................................................................... 1 unit


www.bio-rad.com

Clinical HPLC

Biogenic Amines

Improved manual method and automated method on Gilson ASPEC™

It has been found that in 1 of 200 hypertensive patients, the disease is due to a neuroendocrine tumor(1). Since pheochromocytoma is surgically curable, it is desirable to screen all hypertensive patients.

This HPLC test is designed for the quantitative determination of metanephrine, normetanephrine and 3-methoxy- tyramine in urine, supporting the diagnosis of pheochro-mocytoma and related neurogenic tumors.

In addition, this application is easily compatible with Bio-Rad´s Urinary Catecholamines by HPLC assay because the same analytical cartridge and mobile phase are used.

The Urinary Metanephrines by HPLC assay features:

■■ Fast sample preparation – one disposable column instead of two

■■ Increased reliability - improved separation of metanephrine and normetanephrine - pH indicator in dilution reagent displays optimal pH range

■■ Maximized throughput - simplified test procedure reduces hands-on time - automated application on Gilson ASPEC™ XL or

GX271 available

Sample preparation:



■■ Principle: Isocratic HPLC method (Reversed Phase)■■ Duration of chromatography: 14 minutes■■ Sample volume:

1 mL urine (manual method) 400 μL urine (automated method)

■■ Flow rate: 1.2 mL/min■■ Electrochemical detection: 600 mV

Urinary Metanephrines by HPLC

(1) WHO Library: Kathib OMN: Clinical Guidelines for the Management of Hypertension; EMRO Technical Publications Series; 29; 2005

Chromatogram of the Biogenic Amines Calibrator

Urinary Metanephrines by HPLC

HPLC Automation Bio-Rad has developed automated protocols for many of our HPLC kits by making use of the Gilson ASPEC™ XL or GX-271. Each protocol is validated so you can have confidence in the results. These methods help reduce laboratory costs by dramatically decreasing labour hours. Contact your local Bio-Rad representative for more information about the Gilson ASPEC™ methods.

See Also





Catalog Description

Reagent Kit

195-4129 VMA/HVA/5-HIAA by HPLC Reagent Kit ..................................................................................................... 100 tests195-4135 VMA/HVA/5-HIAA by HPLC Reagent Kit, automated method ..................................................................... 300 tests


195-5961 Analytical Column (includes 1 Micro-Guard™ Cartridge) ....................................................................... 500 injections195-5030 Micro-Guard™ Cartridge Holder ........................................................................................................................ 1 unit195-4088 Capillary Connecting Set................................................................................................................................... 1 unit195-5976 Application CD ROM for Biogenic Amines on ASPEC™ ..................................................................................... 1 unit


www.bio-rad.com

Clinical HPLC

Biogenic Amines

Improved application for VMA only by HPLC. Manual method and automated method on Gilson ASPEC™

This assay permits either simultaneous quantitative determination of vanillylmandelic acid (VMA), homovanillic acid (HVA) and 5-hydroxyindoleacetic acid (5-HIAA) or the quantitative determination of vanillylmandelic acid (VMA) only in urine by HPLC for diagnosis of pheochromocy-toma, neuroblastoma, and carcinoid syndrome.

The VMA/HVA/5-HIAA by HPLC assay features:

■■ Excellent flexibility – simultaneous determination of VMA, HVA and 5-HIAA or determination of VMA only

■■ Maximized throughput – automated application on Gilson ASPEC™ XL or GX271 available

Sample preparation:



■■ Principle: Isocratic HPLC method (Reversed Phase)■■ Duration of chromatography: 19 minutes (for VMA, HVA

and 5-HIAA) or 10 minutes (for VMA only)■■ Sample volume: 50 μL (manual method) / 50 μL (auto-

mated method) urine■■ Flow rate: 1.05 mL/min■■ Electrochemical detection: 750 mV

VMA/HVA/5-HIAA by HPLC

VMA/HVA/5-HIAA by HPLC

Chromatogram of theVMA/HVA/5-HIAA Calibrator (VHH method)

HPLC Automation Bio-Rad has developed automated protocols for many of our HPLC kits by making use of the Gilson ASPEC™ XL or GX-271. Each protocol is validated so you can have confidence in the results. These methods help reduce laboratory costs by dramatically decreasing labour hours. Contact your local Bio-Rad representative for more information about the Gilson ASPEC™ methods.

0.0

2.5

5.0

7.5

10.0

12.5

15.0

17.5

20.0

0.00

0.25

0.50

0.75

1.00

1.25

1.50

Time (min.)

Vol

t

VM

A

HIV

A (

Inte

rnal

Sta

ndar

d 1)

HIC

A (

Inte

rnal

Sta

ndar

d 2)

HV

A

5-H

IAA

See Also



Catalog Description

Reagent Kit

195-5854 Serotonin by HPLC Reagent Kit .................................................................................................................. 100 testsConsisting of:

195-5854R Reagent Set ..................................................................................................................................................... 1 unit195-5859 Calibrator Set ................................................................................................................................................... 1 unit


195-5855 Analytical Column (includes 2 Micro-Guard™ cartridges). ..................................................................... 500 injections195-5030 Micro-Guard™ Cartridge Holder ........................................................................................................................ 1 unit195-4088 Capillary Connecting Set................................................................................................................................... 1 unit196-1012 Sample Vials ............................................................................................................................................. 1000 vials195-5232 Piercable Caps .......................................................................................................................................... 500 caps


www.bio-rad.com

Clinical HPLC

Biogenic Amines

Chromatogram of the Serotonin Urine Standard

Urine control material now available separately

Serotonin plays an important role as a neurotransmitter in the central nervous system, influencing sleep, perception of pain, social behavior and mood.

Tumors like carcinoids, which often become malignant and metastasize, dramatically influence the balance of naturally occurring levels of serotonin.

This assay provides quantitative determination of serotonin in urine and serum by specific and precise HPLC separation for diagnosis and follow-up of patients with carcinoid syndrome.

The improved application provides:

■■ Excellent reliability – separately available, bi-level control

■■ High flexibility – determination of serotonin levels in human serum or urine

Sample preparation:



■■ Principle: Isocratic HPLC method (Reversed Phase)■■ Duration of chromatography: 7.5 minutes■■ Sample volume: 500 μL serum or 1 mL urine■■ Flow rate: 1.0 mL/min■■ Electrochemical detection: 600 mV

Serotonin by HPLC

Serotonin by HPLC

See Also





www.bio-rad.com

Clinical HPLC

Homocysteine Assays

Sample preparation:

■■ Type: Fluorescence labelling with subsequent protein precipitation

■■ Duration: <20 minutes


■■ Principle: Isocratic HPLC method (Reversed Phase)■■ Duration of chromatography: 5 minutes■■ Sample volume: 50 μL plasma or serum■■ Flow rate: 0.7 mL/min■■ Fluorescence Detection: excitation: 385 nm,

emission: 515 nm

Homocysteine by HPLC

Chromatograms of a normal (left) and an elevated (right) patient sample

The presence of elevated total homocysteine levels in plasma or serum has been connected to the increased risk of thrombosis, neural tube defects and atherosclerotic vascular disease. With the steadily growing demand for testing, laboratories require a fast, reliable determination that is cost-effective to process. This application provides a rapid and cost-effective method for quantitative homocysteine analysis in serum or plasma and offers:

■■ Maximized throughput - One-step derivatization & reduction - Five minutes incubation time

■■ Excellent reliability – specific fluorescent labeling which eliminates interfering substances

Homocysteine by HPLC

Homocysteine Assay for Risk Assessment Testing


Catalog Description

Reagent Kit

195-4075 Homocysteine by HPLC ............................................................................................................................. 100 tests


195-4076 Analytical Cartridge (includes 2 Micro-Guard™ Cartridges) ................................................................... 500 injections195-5023 Analytical Cartridge Holder. ............................................................................................................................... 1 unit195-5030 Micro-Guard™ Cartridge Holder......................................................................................................................... 1 unit195-4088 Capillary Connecting Set................................................................................................................................... 1 unit196-1012 Sample Vials .............................................................................................................................................. 1000 vials195-5232 Piercable Caps ........................................................................................................................................... 500 caps195-4089 Test Mix .............................................................................................................................................................2 mL


www.bio-rad.com

Clinical HPLC

Homocysteine Assays

From sample to results in 20 minutes

Homocysteine by HPLC Assay Protocol

of supernatant

See Also





Catalog Description

Reagent Kit

195-9501 Hydroxyproline by HPLC Reagent Kit ......................................................................................................... 100 tests Consisting of:

195-9501R Reagent Set ..................................................................................................................................................... 1 unit195-9515 Mobile Phase Set ....................................................................................................................................... 2 x 2.0 L195-9509 Hydrolysis glass tubes .............................................................................................................................. 100 tubes


195-9520 Analytical Column (includes 2 Micro-Guard™ Cartridges) ..................................................................... 500 injections195-5030 Micro-Guard™ Cartridge Holder ....................................................................................................................... 1 unit195-4088 Capillary Connecting Set .................................................................................................................................. 1 unit196-1012 Sample Vials ............................................................................................................................................. 1000 vials195-5232 Piercable Caps ........................................................................................................................................... 500 caps


www.bio-rad.com

Clinical HPLC

Bone and Mineral Testing

Hydroxyproline is a frequently used marker for bone density. A high secretion of hydroxyproline is of clinical importance and a signal of destructive processes in the skeletal system.

Measurement of hydroxyproline allows early diagnosis and control of progression of bone metastases of malignant diseases as well as control of progression or therapy of osteoporosis, acromegaly, rheumatoid arthritis, or Morbus Paget and diagnosis of hyperparathyroidism.

This assay is intended for the quantitative determination of hydroxyproline in urine.

The Hydroxyproline by HPLC Kit features:

■■ High patient acceptance - Only an 18-hour collagen-free diet is required - Only a 2-hour urine collection is necessary

■■ Improved quality of life - Early diagnosis of malignant diseases

Hydroxyproline by HPLC


Sample preparation:

■■ Type: hydrolysis with subsequent derivatization■■ Duration: including 16h hydrolysis <17h


■■ Principle: Isocratic HPLC method (Reversed Phase)■■ Duration of chromatography: 6 minutes■■ Sample volume: 1 mL urine■■ Flow rate: 1.5 mL/min■■ UV Detection: 471 nm

Hydroxyproline by HPLC Chromatogram of the Hydroxyproline Calibrator

See Also



Catalog Description

Reagent Kit

195-6576 Pyridinium-Crosslinks by HPLC Reagent Kit ............................................................................................... 100 testsConsisting of:

195-6576R Reagent Set .................................................................................................................................................... 1 unit195-6579 Calibrator Set ................................................................................................................................................... 1 unit


195-5929 Analytical Cartridge (includes 2 Micro-Guard™ Cartridges) ................................................................... 500 injections195-5925 Analytical Cartridge Holder ............................................................................................................................... 1 unit195-5030 Micro-Guard™ Cartridge Holder ........................................................................................................................ 1 unit195-4088 Capillary Connecting Set .................................................................................................................................. 1 unit195-5915 Test Mix .........................................................................................................................................................2,5 mL


www.bio-rad.com

Clinical HPLC


Chromatogram of thePyridinium-Crosslinks Test Mix

The pyridinium derivatives, pyridinoline (PYD) and deoxypyridinoline (DPD), are considered to be the most specific markers of bone resorption. Measurement of these biochemical markers of bone metabolism provides information concerning the dynamics of bone transformation and the related loss of bone mass and allows control of progression or therapy of osteoporosis, for example.

This assay is intended for the quantitative determination of pyridinoline (PYD) and deoxypyridinoline (DPD) in urine.

The Pyridinium Crosslinks by HPLC Kit features:

■■ High patient acceptance – no dietary restrictions required

■■ Excellent robustness – interfering substances eliminated during easy specimen preparation

■■ Excellent reliability – Calibrator traceable to CDC Candidate Reference Material

Sample preparation:



■■ Principle: Isocratic HPLC method (Reversed Phase)■■ Duration of chromatography: 16 minutes■■ Sample volume: 150 μL urine■■ Flow rate: 0.7 mL/min■■ Fluorescence Detection: excitation: 295 nm,

emission: 400 nm

Pyridinium Crosslinks by HPLC

Pyridinium Crosslinks by HPLC

See Also





Catalog Description

Reagent Kit

195-4100 25-OH-Vitamin D3/D2 by HPLC Reagent Kit .........................100 tests Consisting of:

195-4100R Reagent Set ....................................... 1 unit195-6527 Serum Calibrator Set .......................... 1 unit


195-4105 Analytical Cartridge (includes 2 Micro-Guard™ Cartridges) .......600 injections195-5925 Analytical Cartridge Holder.................. 1 unit195-5030 Micro-Guard™ Cartridge Holder .......... 1 unit195-4088 Capillary Connecting Set..................... 1 unit195-4097 Test Mix ............................................... 1 mL196-1012 Sample Vials ................................ 1000 vials195-5232 Piercable Caps ..............................500 caps


www.bio-rad.com

Clinical HPLC

Vitamin Assays

Sample preparation:

■■ Type: Precipitation with subsequent centrifugation■■ Duration: <15 minutes


■■ Principle: Isocratic HPLC method (Reversed Phase)■■ Duration of chromatography: 11 minutes■■ Sample volume: 500 μL serum or plasma■■ Flow rate: 1.1 mL/min■■ UV Detection: 265 nm

Chromatogram of the 25-OH vitamin D3/D2 Calibrator

(1) American Journal of Clinical Nutrition 2007;85:1586-1591(2) Medical Journal of Australia 2007;187:59-60

Vitamin D3/D2 by HPLC

Vitamin Assays

Improved application for simultaneous measurement of 25-OH vitamin D3 & D2

Vitamin D is an essential bioregulator of calcium metabolism and thus significant for bone mineralization. Vitamin D deficiency is recognized to be a cause of secondary hyperparathyroidism, increased bone turnover and bone loss (osteopenia) in eldery people. Therefore vitamin D testing is essential in the management of patients with various disorders of calcium metabolism.

Studies have suggested that vitamin D may play a role in protecting against cancer(1) and in regulating normal immune function. Deficiency has been linked with auto-immune conditions such as type 1 diabetes(2), multiple sclerosis and rheumatoid arthritis.

Vitamin D supplementation to prevent and treat deficiency can be provided in the form of 25-OH vitamin D3 or 25-OH vitamin D2. Serum concentration of 25-OH vitamin D has been accepted as the clinical indicator of a patient’s vitamin D status. In order to identify and correct the deficiency of these 25-OH metabolites it becomes more and more essential to measure them accurately.

When an accurate 25-OH vitamin D level is critical for diagnosis or a clinical decision, the Bio-Rad 25-OH vitamin D3/D2 by HPLC assay provides precise and accurate test results for circulating 25-OH vitamin D3 and 25-OH vitamin D2 levels by offering:

■■ New! Improved economic efficiency – lifetime of the analytical cartridge increased by 20% to 600 injections


■■ Maximized efficiency – simultaneous determination of 25-OH vitamin D3 and D2 in a single run

■■ Excellent reliability - - New!: Improved separation of 25-OH vitamin D2 in the chromatogram - Human serum based calibrator traceable to the NIST

Standard Reference Material®

Vitamin D3/D2 by HPLC

See Also



Catalog Description

Reagent Kit

195-5869 Vitamin A/E by HPLC Reagent Kit ............................................................................................................... 100 testsConsisting of:

195-5869R Reagent Set ..................................................................................................................................................... 1 unit195-5878 Calibrator Set ................................................................................................................................................... 1 unit


195-5870C Analytical Cartridge ............................................................................................................................. 600 injections195-6636 Prefilter ............................................................................................................................................................2 units270-0338 Holder for Prefilter ............................................................................................................................................. 1 unit195-5925 Cartridge Holder ............................................................................................................................................... 1 unit196-1012 Sample Vials .............................................................................................................................................. 1000 vials195-5232 Piercable Caps ........................................................................................................................................... 500 caps


www.bio-rad.com

Clinical HPLC

Vitamin Assays

Improved application

Vitamins A and E serve many important functions in the body. Vitamin A, for example, plays a role in vision and immune function. The antioxidant properties of vitamin E are probably the most important and best known.

Deficiencies in these vitamins affect mainly infants and children. According to the WHO, deficiencies can lead to blindness and premature death if not recognized and properly treated.

For patients receiving treatment, supplement therapy has to be monitored carefully to avoid severe side effects of hypervitaminosis. Therefore testing for these vitamins is essential for routine screening & monitoring of patients during treatment.

This assay provides quantitative determination of vitamin A (Retinol) and vitamin E (Tocopherol) in serum by HPLC for diagnosis of vitamin deficiency or to monitor supplement therapy.

The Vitamin A/E by HPLC assay features:

■■ New! Increased economic efficiency – with the lifetime of the analytical cartridge being increased by 20% to 600 injections


■■ Maximized efficiency – simultaneous determination of vitamin A and E in a single run

■■ Excellent reliability – Human serum based calibrator traceable to the NIST Standard Reference Material®

Sample preparation:

■■ Type: Precipitation with subsequent centrifugation■■ Duration: <10 minutes


■■ Principle: Isocratic HPLC method (Reversed Phase)■■ Duration of chromatography: 7 minutes■■ Sample volume: 200 μL serum or plasma■■ Flow rate: 0.6 mL/min■■ UV Detection: 340 nm (Vitamin A), 295 nm (Vitamin E)

Vitamin A/E by HPLC

Chromatogram of vitamin A/E Serum Calibrator

Vitamin A/E by HPLC

See Also





Notes

Alcohol Abuse Monitoring 17 − 18

Therapeutic Drug Monitoring 19 − 26

Drug Screening 27 − 30

Overview: Analytes and Controls 31 − 33

Hard- & Software Requirements 34

Toxicology


www.bio-rad.com

TOXICOLOGY

Alcohol Abuse Monitoring

Sample preparation:

■■ Type: Iron saturation plus protein precipitation■■ Duration: <45 minutes


■■ Principle: Gradient HPLC method (Anion-exchange)■■ Duration of chromatography: 10 minutes■■ Sample volume: 150 μL serum or plasma■■ Flow rate: 1.8 min■■ UV Detection: 460 nm

Ready-Prep %CDT by HPLC™

(1) Helander A, Husa A, Jeppson JO. Improved HPLC Method for Carbohydrate-Deficient Transferrin in Serum. Clin. Chem. 2003; 49:11, 1881-1890

Ready-Prep %CDT by HPLCTM


Simplified test procedure

Currently CDT (carbohydrate deficient transferrin) is the most specific biochemical marker for the detection of alcohol abuse and for monitoring of abstinence during treatment. Daily consumption of 50 - 80 grams ethanol for one week or longer results in elevated levels of %CDT. The Ready-Prep %CDT by HPLC™ assay measures the relative amounts of single transferrin isoforms (e.g. disialotransferrin) to total transferrin.

The Bio-Rad Ready-Prep %CDT by HPLC™ kit is designed for reliable, fast and easy determination of %CDT in human serum.

Sample preparation reagents are provided in a premixed, ready-to-use form. Two kit configurations - for use with either manual or automated dispensing procedures - allow for testing of 100 or 300 samples.

A bi-level calibrator set is available to assist laboratories in the standardization of Bio-Rad %CDT testing.

The Ready-Prep %CDT by HPLC™ assay offers:

■■ Maximum flexibility – includes routine screening and confirmatory testing options

■■ Minimized hands on-time – rapid and convenient sample preparation

■■ Excellent reliability – - Detection of genetic transferrin variants - Human based calibrator traceable to IFCC reference - Excellent correlation with candidate reference method(1)

Scheme of the preparative phase for determining the Ready-Prep %CDT by HPLC™, 100 tests.

For each samplepipette 150 μl ofserum into acorrespondinglylabelled vial, pre- filled with 350 μL of Ready-PrepReagent.

Mixed thoroughlyon a Vortex mixer.

Incubate for aminimum of 30minutes up to amaximum of 60minutes at roomtemperature orincubate up to 24hours at 2-8°C.

Centrifuge for10 minutes at10,000 x g.

Carefully pipette400 μl of the supernatant into anautosampler vial.

For analysis 100 μl are injected.

100 μl0-60 min


Catalog Description

Reagent Kit

195-6670 Ready-Prep %CDT by HPLC™ Reagent Kit ................................................................................................. 100 tests195-6671 Ready-Prep %CDT by HPLC™ Reagent Kit ................................................................................................. 300 tests


195-6662 Analytical Cartridge .............................................................................................................................. 600 injections195-6663 Holder for Analytical and Guard Cartridge ......................................................................................................... 1 unit195-6665 Test Mix .............................................................................................................................................................1 mL195-6666 Vial Hold Down Assembly (online method) ........................................................................................................ 1 unit196-1012 Sample Vials . ............................................................................................................................................ 1000 vials195-5232 Piercable Caps . ......................................................................................................................................... 500 caps


www.bio-rad.com

TOXICOLOGY


Sample from a light drinker (white) compared to a heavy drinker (green)

Chromatogram of a patientwith a BC variant

Chromatogram of a patientwith a CD variant

Ready-Prep %CDT by HPLCTM

See Also





Catalog Description

Reagent Kit

195-5917 Amiodarone by HPLC Reagent Kit ..100 testsConsisting of:

195-5917R Reagent Set ...................................1 unit195-5921 Calibrator Set .................................1 unit


195-5918 Analytical HPLC Cartridge (includes 2 Micro-Guard™ cartridges) ...500 injections195-5023 Analytical Cartridge Holder...............1 unit195-5030 Micro-Guard™ Cartridge Holder .......1 unit195-4088 Capillary Connecting Set .................1 unit195-1012 Sample vials ........................... 1000 vials195-5232 Piercable Caps .........................500 caps


www.bio-rad.com

TOXICOLOGY

Therapeutic Drug Monitoring

Sample preparation:

■■ Type: protein precipitation■■ Duration: <20 minutes


■■ Principle: Isocratic HPLC method (Reversed Phase)■■ Duration of chromatography: 6 minutes■■ Sample volume: 200 μL plasma or serum■■ Flow rate: 0.7 mL/min■■ UV Detection: 242 nm

Amiodarone, an antiarrhythmic drug, is often used when other antiarrhythmic drugs are inefficient. The medication is effective e. g. in controlling reentry-type arrhythmias associated with Wolff-Parkinson-White syndrome.

The known side effects like pulmonary toxicity of Amiodarone necessitate careful monitoring of the serum concentration of the drug.

The Bio-Rad Amiodarone by HPLC Reagent Kit permits therapeutic drug monitoring of amiodarone and its metabolite desethylamiodarone in serum. The Amiodarone by HPLC assay features:

■■ Maximized throughput – only 6 minutes per HPLC run■■ Minimized hands on-time –

- With ready-to-use reagents - Easy specimen preparation

Therapeutic drug monitoring (TDM) is the measurement of drugs at various intervals of treatment in order to maintain a relatively constant concentration of the medication in the bloodstream. TDM is an established procedure for cardiac drugs, antidepressants, antipsychotics, or immunsuppressants for example. Drugs that are monitored tend to have a narrow “therapeutic range”. The concentration required to be effective is not far from the concentration that causes significant side effects and/or signs of toxicity. Maintaining this steady state is not as simple as giving a standard dose of medication. Each person will absorb, metabolize, utilize, and eliminate drugs at a different rate based upon their age, general state of health, genetic make-up, and the interference of other medications that they are taking. Therapeutic drug monitoring is a valid tool to optimize pharmacotherapy. It identifies patient noncompliance, effects of drug interactions, and helps to tailor dosages to fit the current needs of the specific patient.

Amiodarone by HPLC


Chromatogram of Amiodarone Serum Calibrator

0 1 2 3 4 5 6-0.1

0.0

0.1

0.2

0.3

0.4

0.5

0.6

0.7

0.8

Time (min.)

Volts

Amid

aron

e

Des

ethy

lam

idar

one

Amiodaroneby HPLC

See Also



Catalog Description

Reagent Kit

195-6210 Antiepileptics by HPLC Reagent Kit ....................................100 tests Consisting of:195-6210R Reagent Set. ........................................................................... 1 unit195-6205 Calibrator A Set ....................................................................... 1 unit195-6220 Antiepileptics by HPLC Reagent Kit (online method) ..........200 testsConsisting of:195-6220R Reagent Set ............................................................................ 1 unit195-6205 Calibrator A Set ....................................................................... 1 unit 195-5981 Mobile Phase 1 Set ................................................................. 1 unit


195-6206 Analytical Column (includes 1 Micro-Guard™ Cartridge) ...600 injections195-6219 Extraction Cartridge (online method) ............................500 injections195-5030 Micro-Guard™ Cartridge Holder ............................................... 1 unit270-0613 Extraction Cartridge Holder (online method) ............................. 1 unit195-6682 Prefilter Holder (online method) ................................................ 1 unit270-0338 Prefilter Holder ......................................................................... 1 unit195-6636 HPLC Prefilter .........................................................................2 units 195-4088 Capillary Connecting Set.......................................................... 1 unit196-1012 Sample Vials .................................................................... 1000 vials195-5232 Piercable Caps .................................................................. 500 caps195-5898 Test Mix ................................................................................... 2 mL195-5896 Calibrator B Set ................................................................. 2 x 1 mL195-6208 Calibrator C Set ................................................................ 2 x 1 mL195-6215 Control A Set (bi-level) ........................................................ 2 x 1 mL195-6500 Control B Set (bi-level) ........................................................ 2 x 1 mL195-6218 Control C Set (bi-level) ........................................................ 2 x 1 mL


www.bio-rad.com

TOXICOLOGY



■■ Principle: Isocratic HPLC method (Reversed Phase)■■ Duration of the chromatography:

10-14 min. (manual method) / 12-16 min. (online method)■■ Sample volume: 100 μL (manual method) /

40 μL (online method) serum or plasma■■ Flow rate: 0.8 mL/min■■ UV Detection: 210 nm

Antiepileptics by HPLC

Chromatogram of the Antiepileptics Calibrator A

• 10-OH-Carbazepine• Desmethylmeth-suximide• Lamotrigine• Oxcarbazepine*

• Sultiame• Zonisamide• Lacosamid• Eslicarbazepine acetate*

Chromatogram of the Antiepileptics Calibrator B

• Carbamazepine• Carbamazepine-Epoxide• Ethosuximide• Phenobarbital• Phenytoin• Primidone

Chromatogram of the Antiepileptics Calibrator C

• Felbamate

Manual method and automated online method –with expanded analyte panel

This assay is suitable for reliable, fast and easy quantita-tive determination of a broad range of first and second generation antiepileptic drugs in plasma and serum. The analytes can be extracted and separated with a fully automatable method by online column switching between an extraction cartridge and an analytical column.

The Antiepileptics by HPLC assay offers:

■■ New! Broader analyte portfolio – 2 additional antidepressants added

■■ Increased economic efficiency - By ordering the analytes of interest only - Determination of multiple drugs in one run

■■ Minimized hands-on time – online sample preparation

Antiepileptics by HPLC

* This assay does not provide a quantitative test result for this prodrug, but it provides additional valuable information for the inter-pretation of TDM test results

See Also





Catalog Description

Reagent Kit

195-6690 Levetiracetam by HPLC Reagent Kit .......................................................................................................... 100 testsConsisting of:195-6690R Reagent Set .................................................................................................................................................... 1 unit195-6698 Standard Set ................................................................................................................................................... 1 unit


195-6206 Analytical Column (includes 1 Micro-Guard™ Cartridge) ....................................................................... 500 injections195-6003 Micro-Guard™ Cartridge ..................................................................................................................................2 units195-5030 Micro-Guard™ Cartridge Holder ........................................................................................................................ 1 unit195-4088 Capillary Connecting Set................................................................................................................................... 1 unit195-6636 HPLC Prefilter ..................................................................................................................................................2 units270-0338 Prefilter Holder ................................................................................................................................................. 1 unit


www.bio-rad.com

TOXICOLOGY


New application

Levetiracetam is an antiepileptic drug used in the treatment of certain types of seizures in epileptic patients. This assay provides a reliable, easy-to-use method for the quantitative determination of Levetiracetam in plasma and serum.

Customers can easily switch between the Levetiracetam by HPLC and the Antiepileptics by HPLC application as the same analytical column is used with both.

The Levetiracetam by HPLC assay offers:

■■ Maximal compatibility – same analytical column as in the Antiepileptics by HPLC application

■■ Excellent reliability - Separately available calibrator material - Bi-level control set

Sample preparation:



■■ Principle: Isocratic HPLC method (Reversed Phase)■■ Duration of chromatography: 15 minutes■■ Sample volume: 100 μL serum or plasma■■ Flow rate: 0.8 mL/min■■ UV Detection: 210 nm

Levetiracetam by HPLC

Chromatogram of Levetiracetam Calibrator

Levetiracetam by HPLC

See Also



Catalog Description

Reagent Kit

195-5720 TDM by HPLC Basic Reagent Set .. 200 testsConsisting of:195-6686 Mobile Phase 1 Set............................ 1 unit195-6687 Mobile Phase 2 Set ........................... 1 unit195-5702 Extraction Set 1 ................................. 1 unit


195-6684 Analytical Column (includes 2 Micro-Guard™ cartridges) ....600 injections195-5030 Micro-Guard™ Cartridge Holder ......... 1 unit270-0613 Holder for Extraction Cartridge........... 1 unit195-6682 Holder for Prefilter .............................. 1 unit195-6636 HPLC Prefilter ...................................2 units195-4088 Capillary Connecting Set.................... 1 unit196-1012 Sample Vials .............................. 1000 vials195-5232 Piercable Caps .............................500 caps

Modular system: select analyte dependent calibrator & control set

195-6607 Calibrator A (mono-level) ..................... 5 mL195-6606 Calibrator C (mono-level) ................... 5 mL195-6677 Control A Set (bi-level) ................. 2 x 5 mL195-6678 Control C Set (bi-level) ................. 2 x 5 mL195-6626 Internal Standard 1 ............................. 4 mL


www.bio-rad.com

TOXICOLOGY


Online application - fully compatible with Benzo/TCA & SSRIs applications

Bio-Rad´s application for Rapid Analysis of Psychiatric Drugs (RAPsyD) is suitable for reliable, fast and easy simultaneous quantitative measurement of clozapine, olanzapine, quetiapine, risperidone, and their pharma-cologically active metabolites. The antipsychotics are extracted and separated with an HPLC method that involves online column switching between an extraction cartridge and an analytical column.

With its fully automated HPLC method, the RAPsyD assay allows for time-saving and convenient measurement of the prescribed drugs. RAPsyD by HPLC provides physicians with an efficient tool for initial determination of dosage and for subsequent therapeutic drug monitoring.

This application is easily compatible with Bio-Rad´s new SSRIs by HPLC test and also with the Benzo/TCA by HPLC assay because the same core components including analytical column, extraction cartridge and mobile phases are used. The modular concept allows for flexible ordering of required components only.

The RAPsyD by HPLC assay offers:

■■ Economical - Order only the analytes of interest - Determination of multiple drugs in one run


Sample preparation:

■■ Type: online sample preparation■■ Duration: no hands on sample prep required


■■ Principle: Isocratic HPLC method (Reversed Phase)■■ Duration of chromatography: 27 minutes■■ Sample volume: 600 μL serum or plasma■■ Flow rate: 0.8 mL/min■■ UV Detection: 254 nm (clozapine, olanzapine,

quetiapine); 278 nm (risperidone)

RAPsyD by HPLC

RAPsyD by HPLC

Chromatogram of RAPsyD by HPLC Calibrator A• Clozapine• Norclozapine• Olanzapine• Quetiapine

Chromatogram of RAPsyD by HPLC Calibrator C• Risperidone• 9-OH Risperidone

min5 10 15 20 25

mAU

-1

0

1

2

3

4

5

6

7

Clo

zapi

ne

Inte

rnal

Sta

ndar

d 1

Que

tiapi

ne

Ola

nzap

ine

Nor

cloz

apin

e

min5 10 15 20 25

mAU

-1

0

1

2

3

4

5

6

7

Risperidone

9-OH-Risperidone

Inte

rnal

Sta

ndar

d 1

See Also





Catalog Description

Reagent Kit

195-5720 TDM by HPLC Basic Reagent Set .............................................................................................................. 200 testsConsisting of:195-6686 Mobile Phase 1 Set........................................................................................................................................... 1 unit195-6687 Mobile Phase 2 Set........................................................................................................................................... 1 unit195-5702 Extraction Set 1 ................................................................................................................................................ 1 unit


195-6684 Analytical Column (includes 2 Micro-Guard™ cartridges) ...................................................................... 600 injections195-5030 Micro-Guard™ Cartridge Holder ........................................................................................................................ 1 unit195-6682 Holder for Prefilter ............................................................................................................................................. 1 unit270-0613 Holder for Extraction Cartridge.......................................................................................................................... 1 unit195-4088 Capillary Connecting Set................................................................................................................................... 1 unit196-1012 Sample Vials ............................................................................................................................................. 1000 vials195-5232 Piercable Caps ........................................................................................................................................... 500 caps


195-6552 Calibrator A (mono-level) .............................................................................................................................. 1 x 5 mL195-6553 Calibrator B (mono-level).............................................................................................................................. 1 x 5 mL195-6554 Calibrator C (mono-level) ............................................................................................................................. 1 x 5 mL195-6555 Calibrator D (mono-level) ............................................................................................................................. 1 x 5 mL195-6569 Calibrator E (mono-level) .............................................................................................................................. 1 x 5 mL195-6559 Control A Set (bi-level) ........................................................................................................................... 2 x 2 x 5 mL195-6562 Control B Set (bi-level) ........................................................................................................................... 2 x 2 x 5 mL195-6565 Control C Set (bi-level) ........................................................................................................................... 2 x 2 x 5 mL195-6568 Control D Set (bi-level). .......................................................................................................................... 2 x 2 x 5 mL195-6587 Control E Set (bi-level)............................................................................................................................ 2 x 2 x 5 mL195-6626 Internal Standard 1 ...................................................................................................................................... 1 x 4 mL195-6551 Internal Standard 2 ...................................................................................................................................... 1 x 4 mL


www.bio-rad.com

TOXICOLOGY


Online application - fully compatible with RAPsyD & SSRIs applications

This assay provides a reliable, fast and easy-to-use method for the analysis of 25 antidepressants, benzodiazepines, selective serotonin re-uptake inhibitors (SSRIs), and their pharmacologically active metabolites.

New! Included in the panel of antidepressive drugs are clobazam, norclobazam and nitrazepam.

The analytes are extracted and separated by online column switching between an extraction cartridge and an analytical column. With its fully automated HPLC method, this assay allows for time-saving and convenient measurement of prescribed drugs. This application is easily compatible with Bio-Rad´s new SSRIs by HPLC test and also with the RAPsyD by HPLC assay because the same core components including analytical column, extraction cartridge and mobile phases are used. The modular concept allows for flexible ordering of required components only.

The Benzodiazepines & Tricyclics Andidepressants by HPLC Kit offers:

■■ Increased economic efficiency - Order only the analytes of interest - Determination of multiple drugs in one run


Sample preparation:



■■ Principle: Isocratic HPLC method (Reversed Phase)■■ Duration of the chromatography:

34 min (Analyte panel A) / 24 min (Analyte panel B - E)■■ Sample volume: 600 μL serum or plasma■■ Flow rate: 1.1 mL/min (Analyte panel A) / 0.6 mL/min

(Analyte Panel B - E)■■ UV Detection: 250 nm (Analyte panel A, C & E) / 233 nm

(Analyte panel B & D)

Benzodiazepines & Tricyclics Antidepressants by HPLC

See Also



www.bio-rad.com

TOXICOLOGY


Benzodiazepines & Tricyclics Antidepressants by HPLC

Chromatogram of Benzo/TCA by HPLC Calibrator A

• Amitriptyline• Clomipramine• Desipramine• Doxepine• Imipramine• Norclomipramine• Nordoxepine• Nortrimipramine• Nortriptyline• Trimipramine

Chromatogram of Benzo/TCA by HPLC Calibrator B

• Alprazolam• Chlordiazepoxide• Desalkylflurazepam• Diazepam

• Nordiazepam• Oxazepam• Trazodone

Chromatogram of Benzo/TCA by HPLC Calibrator D

• Bromazepam• Lorazepam• Temazepam

Chromatogram of Benzo/TCA by HPLC Calibrator C

• Clonazepam• Flunitrazepam• Nitrazepam

Chromatogram of Benzo/TCA by HPLC Calibrator E

• Clobazam• Norclobazam

min5 10 15 20 25 30

mAU

-2

-1

0

1

2

3

4

5

6

7

Nordo

xepine

Desipramine

Nortriptylin

eNortrim

ipramine

Norclom

ipramine

Doxep

ine

Imipramine

Amitriptylin

e

Clom

ipramine

Trim

ipramine

Inte

rnal

Sta

ndar

d 1

min5 10 15 20

mAU

-5

0

5

10

15

20

Oxazepa

m

Chlordiazepo

xide

Alprazolam

Desalkyl�urazep

am Nordiazep

am

Trazod

one

Diazepa

m

Inte

rnal

Sta

ndar

d 2

min5 10 15 20

mAU

-5

0

5

10

15

20

Brom

azep

am

Lorazepa

m

Temazep

am

Inte

rnal

Sta

ndar

d 2


Catalog Description

Reagent Kit

195-5720 TDM by HPLC Basic Reagent Set ......................................... 200 testsConsisting of:195-6686 Mobile Phase 1 Set...................................................................... 1 unit195-6687 Mobile Phase 2 Set...................................................................... 1 unit195-5702 Extraction Set 1 ........................................................................... 1 unit


195-6684 Analytical Column (includes 2 Micro-Guard™ cartridges) ....600 injections195-5030 Micro-Guard™ Cartridge Holder ................................................... 1 unit195-6682 Holder for Prefilter ........................................................................ 1 unit270-0613 Holder for Extraction Cartridge..................................................... 1 unit195-4088 Capillary Connecting Set.............................................................. 1 unit196-1012 Sample Vials. ........................................................................ 1000 vials195-5232 Piercable Caps ...................................................................... 500 caps195-5734 Extraction Set 2 (for analyte panel “D” and “F”) ............................ 1 unit 195-5807 Sample Loop, 200 μL (for analyte panel “F” only) ......................... 1 unit


195-5710 Calibrator A ............................................................................ 1 x 5 mL195-5711 Calibrator B ............................................................................ 1 x 5 mL 195-5712 Calibrator C ............................................................................ 1 x 5 mL195-5713 Calibrator D ............................................................................ 1 x 5 mL195-5714 Calibrator E............................................................................. 1 x 5 mL195-5715 Calibrator F ............................................................................. 1 x 5 mL195-5706 Control A Set .................................................................... 2 x 2 x 5 mL195-5709 Control B Set .................................................................... 2 x 2 x 5 mL 195-5724 Control C Set .................................................................... 2 x 2 x 5 mL195-5727 Control D Set .................................................................... 2 x 2 x 5 mL195-5730 Control E Set .................................................................... 2 x 2 x 5 mL195-5733 Control F Set .................................................................... 2 x 2 x 5 mL195-6626 Internal Standard 1 ................................................................. 1 x 4 mL195-6551 Internal Standard 2 ................................................................. 1 x 4 mL 195-5983 Internal Standard 3 ................................................................. 1 x 4 mL195-5984 Internal Standard 4 ................................................................. 1 x 4 mL195-5985 Internal Standard 5 ................................................................. 1 x 4 mL


www.bio-rad.com

TOXICOLOGY


Online Application - fully compatible with BENZO/TCA & RAPsyD tests

The method focuses on selective serotonin re-uptake inhibitors (SSRIs), a class of antidepressants considered to be the current standard of drug treatment for depression.

The Bio-Rad SSRIs by HPLC method permits a quick, reproducible, and specific quantification of therapeutic concentrations for 17 drugs and/or their metabolites in serum or plasma.

The analytes are extracted and separated by online column switching between an extraction cartridge and an analytical column. With its fully automated HPLC method, this assay allows for time-saving and convenient measurement of the prescribed drugs. This application is easily compatible with Bio-Rad´s Benzo/TCA by HPLC test and also with the RAPsyD by HPLC assay because the same core components including analytical column, extraction cartridge and mobile phases are used. The modular concept allows for flexible ordering of required components only.

The SSRIs by HPLC assay offers:

■■ New! Broader analyte portfolio – 12 additional antidepressants added

■■ Increased economic efficiency - Order only the analytes of interest - Determination of multiple drugs in one run


Sample preparation:


Test characteristics (depending on analyte panel):

■■ Principle: Isocratic HPLC method (Reversed Phase)■■ Duration of the chromatography: 18 - 30 min■■ Sample volume: 600 - 700 μL serum or plasma■■ Flow rate: 0.8 mL/min■■ UV Detection: 230 - 290 nm■■ Fluorescence Detection: excitation = 230/240 nm,

emission = 310 nm

SSRIs by HPLC

SSRIs by HPLC

See Also



www.bio-rad.com

TOXICOLOGY


Chromatogram of SSRIs by HPLC Calibrator B

• Citalopram• Desmethyl-citalopram• Fluvoxamine

Chromatogram of SSRIs by HPLC Calibrator D

• Desmethyl-mirtazapine 1)

• Paroxetine• Mirtazapine• Reboxetine

Chromatogram of SSRIs by HPLC Calibrator A

• Venlafaxine• O-desmethyl-venlafaxine• N-desmethyl-venlafaxine

Chromatogram of SSRIs by HPLC Calibrator C

• Fluoxetine• Norfluoxetine

Chromatogram of SSRIs by HPLC Calibrator F

• N-desmetyhl-sertraline• SertralineChromatogram of SSRIs by HPLC Calibrator E

• Bupropion • Duloxetine• Hydroxy-bupropion

1) This assay does not provide quantitative test results for pharmacologically inactive metabolites, but it provides additional valuable information for the interpretation of TDM test results


www.bio-rad.com

TOXICOLOGY

Drug Screening

TOX/See™ is a one-step, hand-held, point-of-care test device for the qualitative detection of 14 drugs or drug metabolites in human urine. Bio-Rad’s TOX/See™ product portfolio includes specific tests for drugs of abuse, such as oxycodone, buprenorphine, ecstasy, and propoxyphene to meet today´s customers´ demands and features a variety of combinations of 14 drugs listed below. The simple test protocol is designed for use in hospitals, emergency departments, correctional facilities, juvenile facilities, police departments, workplaces, and recovery and rehabilitation programs.

■■ Walkway flexibility: Test results are stable for reading for up to 1 hour to accommodate busy laboratory schedules.

■■ Comprehensive test panels: Simultaneous detection of as many as 12 drugs per cassette.

■■ Rapid results: Test results are available in 5 minutes.

■■ Differentiate between amphetamine, methamphetamine, and ecstasy in one step: Provides specific

information to clinicians for better patient management.

■■ Specific tests for emerging drugs of abuse: oxycodone, buprenorphine, ecstasy, and propoxyphene.

■■ One-step test protocol: Allows for easy training.

TOX/See™ Rapid Urine Drug Screen Tests

Drug Screening


www.bio-rad.com

TOXICOLOGY

Drug Screening

A One-Step Urine Test for Rapid Drug Screen

TOX/See™ Protocol Sheet

■■ Add 3 drops of urine to each well

■■ Check control line and read results at 5 minutes after the addition of sample

Add Urine Check Control Read Results

The presence of a colored line beside the C (control) serves as verification that:

■■ A sufficient volume of specimen was added

■■ A proper flow was obtained

■■ Results remain stable for up to one hour

■■ Line = negative■■ No line = positive

In the example, the test is positive for COC.

1 2 3

Interpretation

POSITIVE: A colored line in the control region (C) and NO COLORED LINE next to the respective drug name

NEGATIVE: A colored line in the control region (C) and a COLORED LINE next to the respective drug name. Note: The presence of any line, regardless of intensity, should beinterpreted as a negative result

INVALID: a control line fails to appear.

■■ Insufficient specimen or incorrect procedural techniques are most likely reasons for control line failure

■■ Review procedure and repeat the test with a new test device■■ If problem persists, discontinue using the lot immediately and contact

Bio-Rad office

c

coc

c

coc

c

coc

c

coc


www.bio-rad.com

TOXICOLOGY

Drug Screening

Ordering Information

Catalog Description

194-5221 TOX/See™ Drug Screen Test AMP, BAR, BZO, COC, MDMA, MET, MTD, OPI,OXY, PCP,TCA, THC ............. 25 tests

194-5225 TOX/See™ Drug Screen Test AMP, BAR, BZO, COC, MDMA, MET, MTD, OPI, PCP, THC ............................. 25 tests

194-5228 TOX/See™ Drug Screen Test AMP, BAR, BZO, COC, MET, MTD, OPI, PCP, TCA, THC................................. 25 tests

194-5230 TOX/See™ Drug Screen Test AMP, BAR, BZO, COC, MET, OPI,PCP, TCA, THC ........................................... 25 tests

194-5182 TOX/See™ Drug Screen Test AMP, BAR, BZO, COC, MET, MTD, OPI, THC .................................................. 25 tests

194-5183 TOX/See™ Drug Screen Test AMP, BAR, BZO, COC, MTD, OPI 2000, PCP, THC ......................................... 25 tests

194-5209 TOX/See™ Drug Screen Test AMP, BAR, BZO, COC, MTD, OPI, PCP, THC .................................................. 25 tests

194-5216 TOX/See™ Drug Screen Test AMP, BZO, COC, OPI, THC ............................................................................. 25 tests

194-5200 TOX/See™ Drug Screen Test AMP, COC, OPI, PCP, THC .............................................................................. 25 tests

194-5184 TOX/See™ Drug Screen Test AMP. ................................................................................................................ 25 tests

194-5185 TOX/See™ Drug Screen Test BAR ................................................................................................................. 25 tests

194-5205 TOX/See™ Drug Screen Test BUP. ................................................................................................................ 25 tests

194-5186 TOX/See™ Drug Screen Test BZO ................................................................................................................. 25 tests

194-5188 TOX/See™ Drug Screen Test COC ................................................................................................................ 25 tests

194-5224 TOX/See™ Drug Screen Test MDMA ............................................................................................................. 25 tests

194-5190 TOX/See™ Drug Screen Test MET ................................................................................................................. 25 tests

194-5191 TOX/See™ Drug Screen Test MTD ................................................................................................................ 25 tests

194-5192 TOX/See™ Drug Screen Test OPI .................................................................................................................... 5 tests

194-5203 TOX/See™ Drug Screen Test OXY. ................................................................................................................ 25 tests

194-5194 TOX/See™ Drug Screen Test PCP ................................................................................................................. 25 tests

194-5204 TOX/See™ Drug Screen Test PPX ................................................................................................................... 5 tests

194-5234 TOX/See™ Drug Screen Test TCA ................................................................................................................. 25 tests194-5187 TOX/See™ Drug Screen Test THC ................................................................................................................. 25 tests

Intended Use of TOX/See™ Drug Screen Test

■■ This assay provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. The preferred method for confirmation testing and the method estab-lished by the Substance Abuse and Mental Health Services Administration (SAMHSA) is gas chromatography/mass spectrometry (GC/MS).

■■ Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary results are used.

■■ The use of external positive and negative control material is recommended to test each new lot or shipment of product and every 30 days thereafter.

■■ This protocol sheet is only for general instructions only. The number of drugs and strips may vary depending on which product has been ordered. For specific information, please refer to the package insert.

Our Tests Feature a Combination of the Following Drugs at These Cutoffs:

Amphetamine AMP. ................ 1000 ng/mLOpiates OPI .............................. 300 ng/mLOpiates OPI2000 .................... 2000 ng/mLBenzodiazepines BZO .............. 300 ng/mLMethadone MTD ...................... 300 ng/mL

Cocaine COC ........................... 300 ng/mLOxycodone OXY. ...................... 100 ng/mLBuprenorphine BUP. ................... 10 ng/mLTetrahydrocannabinol THC. ........ 50 ng/mLMethamphetamine MET. ......... 1000 ng/mL

Barbiturates BAR ...................... 300 ng/mLTricyclic Antidepressants TCA .. 1000 ng/mLEcstasy MDMA ......................... 500 ng/mLPhencyclidine PCP. ..................... 25 ng/mLPropoxyphene PPX. ................. 300 ng/mL


www.bio-rad.com

Clinical HPLC & Toxicology

Overview: Analytes and Controls

An

alyt

eS

amp

le s

pec

imen

Kit

No

. O

f te

sts

Cat

alo

g

nu

mb

er

Au

tom

atio

n o

r o

nlin

e m

eth

od

av

aila

ble

Co

ntr

ols

Pag

e

Uri

ne

Pla

sma

Ser

um

Cat

alo

g n

um

ber

10-O

H-C

arb

aze

pin

e•

•A

ntie

pile

ptic

s by

HP

LC10

0

200

195-

6210

195-

6220

•19

5-62

15

Con

trol

A S

et (b

i-lev

el) f

or A

ntie

pile

ptic

s by

HP

LC20

3-M

eth

oxy

tyra

min

e•

Urin

ary

Met

anep

hrin

es

100

200

195-

5411

195-

5412

•37

5x

376

377

Lyp

hoch

ek® Q

uant

itativ

e U

rine

Con

trol

Min

iPak

(bi-l

evel

)

Lyp

hoch

ek® Q

uant

itativ

e U

rine

Con

trol

, Nor

mal

Lev

el

Lyp

hoch

ek® Q

uant

itativ

e U

rine

Con

trol

, Ab

orm

al L

evel

6

5-H

ydro

xyin

do

lea

ce

tic

ac

id

(5-H

IAA

)•

VM

A/H

VA/5

-HIA

A b

y H

PLC

100

300

195-

4129

195-

4135

•37

5x

376

377

Lyp

hoch

ek® Q

uant

itativ

e U

rine

Con

trol

Min

iPak

(bi-l

evel

)

Lyp

hoch

ek® Q

uant

itativ

e U

rine

Con

trol

, Nor

mal

Lev

el

Lyp

hoch

ek® Q

uant

itativ

e U

rine

Con

trol

, Ab

orm

al L

evel

7

9-O

H R

isp

eri

do

ne

••

RA

Psy

D b

y H

PLC

200

195-

5720

•19

5-66

78C

ontr

ol C

Set

(bi-l

evel

) for

RA

Psy

D b

y H

PLC

22

Alp

razo

lam

••

Ben

zod

iaze

pin

es &

Tric

yclic

ant

idep

ress

ants

by

HP

LC20

019

5-57

20•

195-

6562

C

ontr

ol B

Set

(bi-l

evel

) for

Ben

zo/T

CA

by

HP

LC23

-24

Am

iod

aro

ne

•A

mio

dar

one

by H

PLC

100

195-

5917

Am

iod

aron

e C

ontr

ol c

omm

erci

ally

ava

ilab

le (e

.g. U

TAK

Ser

um T

oxic

olog

y

Con

trol

Bi-

Leve

l Am

iod

aron

e m

id-r

ange

cat

. no.

610

13; h

igh

rang

e ca

t. no

. 610

12)

19

Am

itri

pty

line

••

Ben

zod

iaze

pin

es &

Tric

yclic

ant

idep

ress

ants

by

HP

LC20

019

5-57

20•

195-

6559

Con

trol

A S

et (b

i-lev

el) f

or B

enzo

/TC

A b

y H

PLC

23-2

4

Bro

ma

zep

am

••

Ben

zod

iaze

pin

es &

Tric

yclic

ant

idep

ress

ants

by

HP

LC20

019

5-57

20•

195-

6568

Con

trol

D S

et (b

i-lev

el) f

or B

enzo

/TC

A b

y H

PLC

23-2

4

Bu

pro

pio

n•

•S

SR

Is b

y H

PLC

200

195-

5720

•19

5-57

30S

SR

Is C

ontr

ol E

Set

(bi-l

evel

)25

-26

Ca

rba

ma

zep

ine

••

Ant

iep

ilept

ics

by H

PLC

100

200

195-

6210

195-

6220

•19

5-65

00

Con

trol

B S

et (b

i-lev

el) f

or A

ntie

pile

ptic

s by

HP

LC20

Ca

rba

ma

zep

ine

-Ep

oxi

de

••

Ant

iep

ilept

ics

by H

PLC

100

200

195-

6210

195-

6220

•19

5-65

00

Con

trol

B S

et (b

i-lev

el) f

or A

ntie

pile

ptic

s by

HP

LC20

Ca

rbo

hyd

rate

de

fic

ien

t

tra

nsf

err

in•

Rea

dy-

Pre

p %

CD

T by

HP

LC10

0

300

195-

6670

195-

6671

195-

6669

C

ontr

ol S

et (b

i-lev

el) f

or R

ead

y P

rep

%C

DT

by H

PLC

17-1

8

Ch

lord

iaze

po

xid

e•

•B

enzo

dia

zep

ines

& T

ricyc

lic a

ntid

epre

ssan

ts b

y H

PLC

200

195-

5720

•19

5-65

62

Con

trol

B S

et (b

i-lev

el) f

or B

enzo

/TC

A b

y H

PLC

23-2

4

Cit

alo

pra

m•

•S

SR

Is b

y H

PLC

200

195-

5720

•19

5-57

09S

SR

Is C

ontr

ol B

Set

(bi-l

evel

)25

-26

Clo

ba

zam

••

Ben

zod

iaze

pin

es &

Tric

yclic

ant

idep

ress

ants

by

HP

LC20

019

5-57

20•

195-

6587

Con

trol

E S

et (b

i-lev

el) f

or B

enzo

/TC

A b

y H

PLC

23-2

4

Clo

mip

ram

ine

••

Ben

zod

iaze

pin

es &

Tric

yclic

ant

idep

ress

ants

by

HP

LC20

019

5-57

20•

195-

6559

Con

trol

A S

et (b

i-lev

el) f

or B

enzo

/TC

A b

y H

PLC

23-2

4

Clo

na

zep

am

••

Ben

zod

iaze

pin

es &

Tric

yclic

ant

idep

ress

ants

by

HP

LC20

019

5-57

20•

195-

6565

C

ontr

ol C

Set

(bi-l

evel

) for

Ben

zo/T

CA

by

HP

LC23

-24

Clo

zap

ine

••

RA

Psy

D b

y H

PLC

200

195-

5720

•19

5-66

77C

ontr

ol A

Set

(bi-l

evel

) for

RA

Psy

D b

y H

PLC

22

De

seth

yla

mio

da

ron

e•

•A

mio

dar

one

by H

PLC

100

195-

5917

Am

iod

aron

e C

ontr

ol c

omm

erci

ally

ava

ilab

le (e

.g. U

TAK

Ser

um T

oxic

olog

y C

ontr

ol

Bi-

Leve

l Am

iod

aron

e m

id-r

ange

cat

. no.

610

13; h

igh

rang

e ca

t. no

. 610

12)

19

De

oxy

pyr

idin

olin

e•

Pyr

idin

ium

cro

sslin

ks b

y H

PLC

100

195-

6576

195-

5959

Pyr

idin

ium

-Cro

sslin

ks b

y H

PLC

Con

trol

Set

(bi-l

evel

)12

De

salk

ylfl

ura

zep

am

••

Ben

zod

iaze

pin

es &

Tric

yclic

ant

idep

ress

ants

by

HP

LC20

019

5-57

20•

195-

6562

C

ontr

ol B

Set

(bi-l

evel

) for

Ben

zo/T

CA

by

HP

LC23

-24

De

sip

ram

ine

••

Ben

zod

iaze

pin

es &

Tric

yclic

ant

idep

ress

ants

by

HP

LC20

019

5-57

20•

195-

6559

Con

trol

A S

et (b

i-lev

el) f

or B

enzo

/TC

A b

y H

PLC

23-2

4

De

sme

thyl

-cit

alo

pra

m•

•S

SR

Is b

y H

PLC

200

195-

5720

•19

5-57

09S

SR

Is C

ontr

ol B

Set

(bi-l

evel

)25

-26

De

sme

thyl

me

thsu

xim

ide

••

Ant

iep

ilept

ics

by H

PLC

100

200

195-

6210

195-

6220

•19

5-62

15C

ontr

ol A

Set

(bi-l

evel

) for

Ant

iep

ilept

ics

by H

PLC

20

De

sme

thyl

-mir

taza

pin

e•

•S

SR

Is b

y H

PLC

200

195-

5720

•19

5-57

27S

SR

Is C

ontr

ol D

Set

(bi-l

evel

)25

-26

Dia

zep

am

••

Ben

zod

iaze

pin

es &

Tric

yclic

ant

idep

ress

ants

by

HP

LC20

019

5-57

20•

195-

6562

C

ontr

ol B

Set

(bi-l

evel

) for

Ben

zo/T

CA

by

HP

LC23

-24

Do

pa

min

e•

Urin

ary

Cat

echo

lam

ines

by

HP

LC

100

300

195-

5390

195-

5391

•37

5x

376

377

Lyp

hoch

ek® Q

uant

itativ

e U

rine

Con

trol

Min

iPak

(bi-l

evel

)

Lyp

hoch

ek® Q

uant

itativ

e U

rine

Con

trol

, Nor

mal

Lev

el

Lyp

hoch

ek® Q

uant

itativ

e U

rine

Con

trol

, Ab

orm

al L

evel

4

•P

lasm

a C

atec

hola

min

es b

y H

PLC

100

195-

5880

535x

Lyp

hoch

ek® E

ndoc

rine

Con

trol

, Min

iPak

(bi-l

evel

)5

Do

xep

ine

••

Ben

zod

iaze

pin

es &

Tric

yclic

ant

idep

ress

ants

by

HP

LC20

019

5-57

20•

195-

6559

Con

trol

A S

et (b

i-lev

el) f

or B

enzo

/TC

A b

y H

PLC

23-2

4

Du

loxe

tin

e•

•S

SR

Is b

y H

PLC

200

195-

5720

•19

5-57

30S

SR

Is C

ontr

ol E

Set

(bi-l

evel

) for

Ben

zo/T

CA

by

HP

LC25

-26

Ep

ine

ph

rin

e•

Urin

ary

Cat

echo

lam

ines

by

HP

LC

100

300

195-

5390

195-

5391

•37

5x

376

377

Lyp

hoch

ek® Q

uant

itativ

e U

rine

Con

trol

Min

iPak

(bi-l

evel

)

Lyp

hoch

ek® Q

uant

itativ

e U

rine

Con

trol

, Nor

mal

Lev

el

Lyp

hoch

ek® Q

uant

itativ

e U

rine

Con

trol

, Ab

orm

al L

evel

4

•P

lasm

a C

atec

hola

min

es b

y H

PLC

100

195-

5880

535x

Lyp

hoch

ek® E

ndoc

rine

Con

trol

, Min

iPak

(bi-l

evel

)5


An

alyt

eS

amp

le s

pec

imen

Kit

No

. O

f te

sts

Cat

alo

g

nu

mb

er

Au

tom

atio

n o

r o

nlin

e m

eth

od

av

aila

ble

Co

ntr

ols

Pag

e

Uri

ne

Pla

sma

Ser

um

Cat

alo

g n

um

ber

Esl

ica

rba

zep

ine

••

Ant

iep

ilept

ics

by H

PLC

100

200

195-

6210

195-

6220

•19

5-62

15

Con

trol

A S

et (b

i-lev

el) f

or A

ntie

pile

ptic

s by

HP

LC20

Eth

osu

xim

ide

••

Ant

iep

ilept

ics

by H

PLC

100

200

195-

6210

195-

6220

•19

5-65

00

Con

trol

B S

et (b

i-lev

el) f

or A

ntie

pile

ptic

s by

HP

LC20

Fe

lba

ma

te•

•A

ntie

pile

ptic

s by

HP

LC10

0

200

195-

6210

195-

6220

•19

5-62

18C

ontr

ol C

Set

(bi-l

evel

) for

Ant

iep

ilept

ics

by H

PLC

20

Flu

nit

raze

pa

m•

•B

enzo

dia

zep

ines

& T

ricyc

lic a

ntid

epre

ssan

ts b

y H

PLC

200

195-

5720

•19

5-65

65

Con

trol

C S

et (b

i-lev

el) f

or B

enzo

/TC

A b

y H

PLC

23-2

4

Flu

oxe

tin

e•

•S

SR

Is b

y H

PLC

200

195-

5720

•19

5-57

24S

SR

Is C

ontr

ol C

Set

25-2

6

Flu

voxa

min

e•

•S

SR

Is b

y H

PLC

200

195-

5720

•19

5-57

09S

SR

Is C

ontr

ol B

Set

(bi-l

evel

)25

-26

Ho

mo

cys

tein

e•

•H

omoc

yste

ine

by H

PLC

100

195-

4075

195-

4085

Hom

ocys

tein

e C

ontr

ol S

et (b

i-lev

el)

9

Ho

mo

van

illic

ac

id (

HV

A)

•V

MA

/HVA

/5-H

IAA

by

HP

LC

100

300

195-

4129

195-

4135

•37

5x

376

377

Lyp

hoch

ek® Q

uant

itativ

e U

rine

Con

trol

Min

iPak

(bi-l

evel

)

Lyp

hoch

ek® Q

uant

itativ

e U

rine

Con

trol

, Nor

mal

Lev

el

Lyp

hoch

ek® Q

uant

itativ

e U

rine

Con

trol

, Ab

orm

al L

evel

7

Hyd

roxy

-bu

pro

pio

n•

•S

SR

Is b

y H

PLC

200

195-

5720

•19

5-57

30S

SR

Is C

ontr

ol E

Set

(bi-l

evel

)25

-26

Hyd

roxy

pro

line

•H

ydro

xyp

rolin

e by

HP

LC

100

195-

9501

375x

376

377

Lyp

hoch

ek® Q

uant

itativ

e U

rine

Con

trol

Min

iPak

(bi-l

evel

)

Lyp

hoch

ek® Q

uant

itativ

e U

rine

Con

trol

, Nor

mal

Lev

el

Lyp

hoch

ek® Q

uant

itativ

e U

rine

Con

trol

, Ab

orm

al L

evel

11

Imip

ram

ine

••

Ben

zod

iaze

pin

es &

Tric

yclic

ant

idep

ress

ants

by

HP

LC20

019

5-57

20•

195-

6559

Con

trol

A S

et (b

i-lev

el) f

or B

enzo

/TC

A b

y H

PLC

23-2

4

La

co

sam

ide

••

Ant

iep

ilept

ics

by H

PLC

100

200

195-

6210

195-

6220

•19

5-62

15

Con

trol

A S

et (b

i-lev

el) f

or A

ntie

pile

ptic

s by

HP

LC20

La

mo

trig

ine

••

Ant

iep

ilept

ics

by H

PLC

100

200

195-

6210

195-

6220

•19

5-62

15

Con

trol

A S

et (b

i-lev

el) f

or A

ntie

pile

ptic

s by

HP

LC20

Lev

eti

rac

eta

m•

•Le

vetir

acet

am b

y H

PLC

100

195-

6690

195-

6695

Con

trol

Set

(bi-l

evel

) for

Lev

etira

ceta

m b

y H

PLC

21

Lo

raze

pa

m•

•B

enzo

dia

zep

ines

& T

ricyc

lic a

ntid

epre

ssan

ts b

y H

PLC

200

195-

5720

•19

5-65

68C

ontr

ol D

Set

(bi-l

evel

) for

Ben

zo/T

CA

by

HP

LC23

-24

Me

tan

ep

hri

ne

•U

rinar

y M

etan

ephr

ines

100

200

195-

5411

195-

5412

•37

5x

376

377

Lyp

hoch

ek® Q

uant

itativ

e U

rine

Con

trol

Min

iPak

(bi-l

evel

)

Lyp

hoch

ek® Q

uant

itativ

e U

rine

Con

trol

, Nor

mal

Lev

el

Lyp

hoch

ek® Q

uant

itativ

e U

rine

Con

trol

, Ab

orm

al L

evel

6

Mir

taza

pin

e•

•S

SR

Is b

y H

PLC

200

195-

5720

•19

5-57

27S

SR

Is C

ontr

ol D

Set

(bi-l

evel

)25

-26

N-d

esm

eth

yl-v

en

lafa

xin

e•

•S

SR

Is b

y H

PLC

200

195-

5720

•19

5-57

06S

SR

Is C

ontr

ol A

Set

(bi-l

evel

)25

-26

N-d

esm

ety

hl-

sert

ralin

e•

•S

SR

Is b

y H

PLC

200

195-

5720

•19

5-57

33S

SR

Is C

ontr

ol F

Set

(bi-l

evel

)25

-26

Nit

raze

pa

m•

•B

enzo

dia

zep

ines

& T

ricyc

lic a

ntid

epre

ssan

ts b

y H

PLC

200

195-

5720

•19

5-65

65

Con

trol

C S

et (b

i-lev

el) f

or B

enzo

/TC

A b

y H

PLC

23-2

4

No

rclo

ba

zam

••

Ben

zod

iaze

pin

es &

Tric

yclic

ant

idep

ress

ants

by

HP

LC20

019

5-57

20•

195-

6587

Con

trol

E S

et (b

i-lev

el) f

or B

enzo

/TC

A b

y H

PLC

23-2

4

No

rclo

mip

ram

ine

••

Ben

zod

iaze

pin

es &

Tric

yclic

ant

idep

ress

ants

by

HP

LC20

019

5-57

20•

195-

6559

Con

trol

A S

et (b

i-lev

el) f

or B

enzo

/TC

A b

y H

PLC

23-2

4

No

rclo

zap

ine

••

RA

Psy

D b

y H

PLC

200

195-

5720

•19

5-66

77C

ontr

ol A

Set

(bi-l

evel

) for

RA

Psy

D b

y H

PLC

22

No

rdia

zep

am

••

Ben

zod

iaze

pin

es &

Tric

yclic

ant

idep

ress

ants

by

HP

LC20

019

5-57

20•

195-

6562

C

ontr

ol B

Set

(bi-l

evel

) for

Ben

zo/T

CA

by

HP

LC23

-24

No

rdo

xep

ine

••

Ben

zod

iaze

pin

es &

Tric

yclic

ant

idep

ress

ants

by

HP

LC20

019

5-57

20•

195-

6559

Con

trol

A S

et (b

i-lev

el) f

or B

enzo

/TC

A b

y H

PLC

23-2

4

No

rep

ine

ph

rin

e•

Urin

ary

Cat

echo

lam

ines

by

HP

LC

100

300

195-

5390

195-

5391

•37

5x

376

377

Lyp

hoch

ek® Q

uant

itativ

e U

rine

Con

trol

Min

iPak

(bi-l

evel

)

Lyp

hoch

ek® Q

uant

itativ

e U

rine

Con

trol

, Nor

mal

Lev

el

Lyp

hoch

ek® Q

uant

itativ

e U

rine

Con

trol

, Ab

orm

al L

evel

4

•P

lasm

a C

atec

hola

min

es b

y H

PLC

100

195-

5880

535x

Lyp

hoch

ek® E

ndoc

rine

Con

trol

, Min

iPak

(bi-l

evel

)5

No

rflu

oxe

tin

e•

•S

SR

Is b

y H

PLC

200

195-

5720

•19

5-57

24S

SR

Is C

ontr

ol C

Set

(bi-l

evel

)25

-26

No

rme

tan

ep

hri

ne

•U

rinar

y M

etan

ephr

ines

100

200

195-

5411

195-

5412

•37

5x

376

377

Lyp

hoch

ek® Q

uant

itativ

e U

rine

Con

trol

Min

iPak

(bi-l

evel

)

Lyp

hoch

ek® Q

uant

itativ

e U

rine

Con

trol

, Nor

mal

Lev

el

Lyp

hoch

ek® Q

uant

itativ

e U

rine

Con

trol

, Ab

orm

al L

evel

6

No

rtri

mip

ram

ine

••

Ben

zod

iaze

pin

es &

Tric

yclic

ant

idep

ress

ants

by

HP

LC20

019

5-57

20•

195-

6559

Con

trol

A S

et (b

i-lev

el) f

or B

enzo

/TC

A b

y H

PLC

23-2

4

No

rtri

pty

line

••

Ben

zod

iaze

pin

es &

Tric

yclic

ant

idep

ress

ants

by

HP

LC20

019

5-57

20•

195-

6559

Con

trol

A S

et (b

i-lev

el) f

or B

enzo

/TC

A b

y H

PLC

23-2

4

O-d

esm

eth

yl-v

en

lafa

xin

e •

•S

SR

Is b

y H

PLC

200

195-

5720

•19

5-57

06S

SR

Is C

ontr

ol A

Set

(bi-l

evel

)25

-26

Ola

nza

pin

e•

•R

AP

syD

by

HP

LC20

019

5-57

20•

195-

6677

Con

trol

A S

et (b

i-lev

el) f

or R

AP

syD

by

HP

LC22

Oxa

zep

am

••

Ben

zod

iaze

pin

es &

Tric

yclic

ant

idep

ress

ants

by

HP

LC20

019

5-57

20•

195-

6562

C

ontr

ol B

Set

(bi-l

evel

) for

Ben

zo/T

CA

by

HP

LC23

-24


www.bio-rad.com



An

alyt

eS

amp

le s

pec

imen

Kit

No

. O

f te

sts

Cat

alo

g

nu

mb

er

Au

tom

atio

n o

r o

nlin

e m

eth

od

av

aila

ble

Co

ntr

ols

Pag

e

Uri

ne

Pla

sma

Ser

um

Cat

alo

g n

um

ber

Oxc

arb

aze

pin

e•

•A

ntie

pile

ptic

s by

HP

LC10

0

200

195-

6210

195-

6220

•19

5-62

15

Con

trol

A S

et (b

i-lev

el) f

or A

ntie

pile

ptic

s by

HP

LC20

Pa

roxe

tin

e•

•S

SR

Is b

y H

PLC

200

195-

5720

•19

5-57

27S

SR

Is C

ontr

ol D

Set

(bi-l

evel

)25

-26

Ph

en

ob

arb

ita

l•

•A

ntie

pile

ptic

s by

HP

LC10

0

200

195-

6210

195-

6220

•19

5-65

00

Con

trol

B S

et (b

i-lev

el) f

or A

ntie

pile

ptic

s by

HP

LC20

Ph

en

yto

in•

•A

ntie

pile

ptic

s by

HP

LC10

0

200

195-

6210

195-

6220

•19

5-65

00

Con

trol

B S

et (b

i-lev

el) f

or A

ntie

pile

ptic

s by

HP

LC20

Pri

mid

on

e•

•A

ntie

pile

ptic

s by

HP

LC10

0

200

195-

6210

195-

6220

•19

5-65

00

Con

trol

B S

et (b

i-lev

el) f

or A

ntie

pile

ptic

s by

HP

LC20

Pyr

idin

olin

e•

Pyr

idin

ium

cro

sslin

ks b

y H

PLC

100

195-

6576

195-

5959

Pyr

idin

ium

-Cro

sslin

ks b

y H

PLC

Con

trol

Set

(bi-l

evel

)12

Qu

eti

ap

ine

••

RA

Psy

D b

y H

PLC

200

195-

5720

•19

5-66

77C

ontr

ol A

Set

(bi-l

evel

) for

RA

Psy

D b

y H

PLC

22

Re

bo

xeti

ne

••

SS

RIs

by

HP

LC20

019

5-57

20•

195-

5727

SS

RIs

Con

trol

D S

et (b

i-lev

el)

25-2

6

Ris

pe

rid

on

e•

•R

AP

syD

by

HP

LC20

019

5-57

20•

195-

6678

Con

trol

C S

et (b

i-lev

el) f

or R

AP

syD

by

HP

LC22

Se

roto

nin

••

Ser

oton

in b

y H

PLC

100

195-

5854

195-

5988

Urin

e C

ontr

ol S

et (b

i-lev

el) f

or S

erot

onin

by

HP

LC8

Se

rtra

line

••

SS

RIs

by

HP

LC20

019

5-57

20•

195-

5733

SS

RIs

Con

trol

F S

et (b

i-lev

el)

25-2

6

Su

ltia

me

••

Ant

iep

ilept

ics

by H

PLC

100

200

195-

6210

195-

6220

•19

5-62

15

Con

trol

A S

et (b

i-lev

el) f

or A

ntie

pile

ptic

s by

HP

LC20

Tem

aze

pa

m•

•B

enzo

dia

zep

ines

& T

ricyc

lic a

ntid

epre

ssan

ts b

y H

PLC

200

195-

5720

•19

5-65

68C

ontr

ol D

Set

(bi-l

evel

) for

Ben

zo/T

CA

by

HP

LC23

-24

Tra

zod

on

e•

•B

enzo

dia

zep

ines

& T

ricyc

lic a

ntid

epre

ssan

ts b

y H

PLC

200

195-

5720

•19

5-65

62

Con

trol

B S

et (b

i-lev

el) f

or B

enzo

/TC

A b

y H

PLC

23-2

4

Trim

ipra

min

e•

•B

enzo

dia

zep

ines

& T

ricyc

lic a

ntid

epre

ssan

ts b

y H

PLC

200

195-

5720

•19

5-65

59C

ontr

ol A

Set

(bi-l

evel

) for

Ben

zo/T

CA

by

HP

LC23

-24

Va

nill

ylm

an

de

lic a

cid

(V

MA

)•

VM

A/H

VA/5

-HIA

A b

y H

PLC

100

300

195-

4129

195-

4135

•37

6

377

Lyp

hoch

ek® Q

uant

itativ

e U

rine

Con

trol

, Nor

mal

Lev

el

Lyp

hoch

ek® Q

uant

itativ

e U

rine

Con

trol

, Ab

orm

al L

evel

7

Ve

nla

faxi

ne

••

SS

RIs

by

HP

LC20

019

5-57

20•

195-

5706

SS

RIs

Con

trol

A S

et25

-26

Vit

am

in A

••

Vita

min

A/E

by

HP

LC10

019

5-58

6919

5-58

79V

itam

in A

/E S

erum

Con

trol

Set

(bi-l

evel

)14

Vit

am

in D

2•

•V

itam

in D

3/D

2 by

HP

LC10

019

5-41

00

195-

6548

Vita

min

D3/

D2

Ser

um C

ontr

ol S

et (b

i-lev

el)

13

Vit

am

in D

3•

•V

itam

in D

3/D

2 by

HP

LC10

019

5-41

00

195-

6548

Vita

min

D3/

D2

Ser

um C

ontr

ol S

et (b

i-lev

el)

13

Vit

am

in E

••

Vita

min

A/E

by

HP

LC10

019

5-58

6919

5-58

79V

itam

in A

/E S

erum

Con

trol

Set

(bi-l

evel

)14

Zo

nis

am

ide

••

Ant

iep

ilept

ics

by H

PLC

100

200

195-

6210

195-

6220

•19

5-62

15

Con

trol

A S

et (b

i-lev

el) f

or A

ntie

pile

ptic

s by

HP

LC20


www.bio-rad.com



HP

LC M

OD

UL

ES

(Har

dw

are)

Rec

om

men

ded

So

ftw

are

solu

tio

ns

Ap

plic

atio

ns

Deg

ass

erIs

ocr

atic

P

um

pQ

uat

ern

ary

Pu

mp

Au

tosa

mp

ler

Co

lum

n H

eate

r U

V/V

IS

Det

ecto

r

Ele

ctro

chem

ical

D

etec

tor

+ A

/D In

terf

ace

Bo

x

Flu

ore

scen

ce

Det

ecto

r

Au

tom

ate

d

sam

ple

p

rep

arat

ion

Inst

ant

Pilo

t +

C

DM

So

ftw

are

Ag

ilen

t C

hem

Sta

tio

n S

oft

war

e

Bio

ge

nic

A

min

es

Uri

nar

y C

atec

ho

lam

ines

19

5-53

90 R

eage

nt K

it 10

0 te

sts

19

5-53

91 R

eage

nt K

it, A

utom

ated

Met

hod

300

test

s 19

5-53

69 A

naly

tical

Car

trid

ge 5

00

inje

ctio

ns

√√

√√

√√

(for

auto

mat

ed

met

hod

only

)√

√

Pla

sma

Cat

ech

ola

min

es

195-

5880

Rea

gent

Kit

100

test

s 19

5-58

86 A

naly

tical

Car

trid

ge 5

00

inje

ctio

ns√

√√

√√

√√

Uri

nar

y M

etan

eph

rin

es

195-

5411

Rea

gent

Kit

100

test

s 19

5-54

12 R

eage

nt K

it, A

utom

ated

Met

hod

200

test

s 19

5-53

69 A

naly

tical

Car

trid

ge 5

00

inje

ctio

ns

√√

√√

√√

(for

auto

mat

ed

met

hod

only

)√

√

VM

A/H

VA

/5-H

IAA

19

5-41

29 R

eage

nt K

it 10

0 te

sts

195-

4135

Rea

gent

Kit,

Aut

omat

ed M

etho

d 30

0 te

sts

195-

5961

Ana

lytic

al C

artr

idge

50

0 in

ject

ions

√√

√√

√√

(for

auto

mat

ed

met

hod

only

)√

√

Ser

oto

nin

19

5-58

54 R

eage

nt K

it 10

0 te

sts

195-

5855

Ana

lytic

al C

artr

idge

50

0 in

ject

ions

√√

√√

√√

√

Ca

rdio

vasc

ula

rH

om

ocy

stei

ne

195-

4075

Rea

gent

Kit

100

test

s 19

5-40

76 A

naly

tical

Car

trid

ge 5

00

inje

ctio

ns√

√√

√√

√√

Bo

ne

&

Min

era

l

Hyd

roxy

pro

line

195-

9501

Rea

gent

Kit

100

test

s 19

5-95

20 A

naly

tical

Col

umn

500

inje

ctio

ns√

√√

√√

√√

Pyr

idin

ium

Cro

sslin

ks

195-

6576

Rea

gent

Kit

100

test

s 19

5-59

29 A

naly

tical

Car

trid

ge 5

00

inje

ctio

ns√

√√

√√

√√

Vit

amin

D3

195-

410

0 R

eage

nt K

it 10

0 te

sts

195-

4105

Ana

lytic

al C

artr

idge

60

0 in

ject

ions

√√

√√

√√

√

Vit

am

ine

sV

itam

in A

/E

195-

5869

Rea

gent

Kit

100

test

s 19

5-58

70C

Ana

lytic

al C

artr

idge

60

0 in

ject

ions

√√

√√

√√

√

TD

M/

Toxi

co

log

y

CD

T b

y H

PLC

19

5-66

70 R

eage

nt K

it 10

0 te

sts

195-

6671

Rea

gent

Kit,

Aut

omat

ed M

etho

d 30

0 te

sts

195-

6662

Ana

lytic

al C

artr

idge

60

0 in

ject

ions

√√

√√

√√

(for

auto

mat

ed

met

hod

only

)√

√

Am

iod

aro

ne

195-

5917

Rea

gent

Kit

100

test

s 19

5-59

18 A

naly

tical

Car

trid

ge 5

00

inje

ctio

ns√

√√

√√

√√

RA

Psy

D b

y H

PLC

19

5-57

20 T

DM

Rea

gent

Kit

200

test

s 19

5-66

84 A

naly

tical

Car

trid

ge 6

00

inje

ctio

ns√

√ (2

isoc

ratic

p

ump

s)√

√√

√√

Ben

zod

iaze

pin

es &

Tri

cycl

ics

195-

5720

TD

M R

eage

nt K

it 20

0 te

sts

195-

6684

Ana

lytic

al C

artr

idge

60

0 in

ject

ions

√√

√√

√√

√

An

tiep

ilep

tics

by

HP

LC

195-

6210

Rea

gent

Kit

100

test

s

195-

6220

Rea

gent

Kit,

Onl

ine

Met

hod

200

test

s

195-

6206

Ana

lytic

al C

artr

idge

50

0 in

ject

ions

√

√ (fo

r on

line

met

hod

2 is

ocra

tic

pum

ps)

√√

√√

√

SS

RIs

19

5-57

20 T

DM

Rea

gent

Kit

200

test

s 19

5-66

84 A

naly

tical

Car

trid

ge 6

00

inje

ctio

ns√

√ (2

isoc

ratic

p

ump

s)√

√√

(for

cert

ain

anal

ytes

)

√

(fo

r ce

rtai

n an

alyt

es)

√√

Lev

etir

acte

tam

19

5-66

90 R

eage

nt K

it 10

0 te

sts

195-

6206

Ana

lytic

al C

artr

idge

50

0 in

ject

ions

√√

√√

√√

√


www.bio-rad.com


Hard-& Software requirements for the clinical HPLC Kits


www.bio-rad.com

Notes

Visit us on the Webwww.bio-rad.com

For further information, please contact your local Bio-Rad office or visit our website at www.bio-rad.com/diagnostics

Clinical Diagnostics Group

© 2016 Bio-Rad Laboratories, Inc. Printed in Germany EU-HPLC-103-02/16E Rev. 02/2016

Website www.bio-rad.com/diagnostics Australia 61-2-9914-2800 Austria 43-1-877-8901 Belgium 32-9-385-5511 Brazil +55 (31)3689-6600 Canada 1-514-334-4372 China 86-21-61698500 Czech Republic 420-241-430-532 Denmark +45-4452-1000 Finland 358-9-804-22-00 France 33-1-47-95-60-00 Germany +49 (0)89-318-840Greece 30-210-7774396 Hong Kong 852-2789-3300 Hungary +36-1-459-6100 India 1800-180-1224 Israel 972-3-9636050 Italy +39-02-216091 Japan 81-3-6361-7070 Korea 82-2-3473-4460 Mexico +52 (55)5488-7670 The Netherlands +31-318-540666 New Zealand 64-9-415-2280 Norway +47-23-38-41-30 Poland 48-22-3319999 Portugal 351-21-472-7700 Russia +7-495-721-1404 Singapore 65-6415-3170 South Africa 27-11-442-85-08 Spain 34-91-590-5200 Sweden +46-8-555-127-00 Switzerland +41 (0)26-674-55-05/06 Taiwan 886-2-2578-7189 Thailand 662-651-8311 United Kingdom +44 (0)20-8328-2000

clinical hplc and toxicology 2016/2017€¦ · clinical hplc and toxicology 2016/2017 at bio-rad,...

Documents